Medical devices, healthcare technology and the business of care
510(k) clearance · K262627

Fractional CO2 Laser Therapy System (Z121)

Sanhe PERFECTLASER Technology Co., Ltd. · Decision date Oct 26, 2026

MEDTECHLEDGER EXPLANATIONK262627

What did the FDA decide?

On October 26, 2026, FDA recorded a substantially equivalent (SE) 510(k) decision for K262627, the Fractional CO2 Laser Therapy System (Z121), submitted by Sanhe PERFECTLASER Technology Co., Ltd. through correspondent Beijing Believe-Med Technology Service Co., Ltd. The device is a Class II laser surgical instrument under 21 CFR 878.4810, product code GEX, reviewed by the General and Plastic Surgery panel. SE clearance is not premarket approval.

The 510(k) summary identifies K241670 (Beijing ADSS Development Co., Ltd.) as predicate and K162169 (Jeisys Medical Inc.) as a reference device, and lists a 10.6 μm wavelength with maximum output power of 35 W, matching the predicate. The stated indications cover body soft tissue ablation, vaporization, excision and coagulation in dermatology, plastic surgery and general surgery, with fractional functionality limited to skin resurfacing. The record does not include clinical performance data, so comparative safety or effectiveness beyond the summary comparison remains unknown.

The summary describes user-set treatment parameters such as laser energy density but gives no specific settings, and the source does not state whether any components or features changed relative to the predicate.

Regulatory pathway
510(k) premarket notification
Clinical specialty
General, Plastic Surgery
Decision date
Oct 26, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K262627
Regulatory pathway
510(k) premarket notification
Product code
GEX
Decision code
SESE
Decision date
Oct 26, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Powered Laser Surgical Instrument.

Product code
GEX
FDA device class
2

FDA decision timeline

  1. K262627 received

    Application receipt date recorded by FDA.

  2. K262627 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code GEX

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Sanhe PERFECTLASER Technology Co., Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Langfang

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records